𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Functional outcome of patients with salvageable limbs with grades III-B and III-C open fractures of the tibia

✍ Scribed by Rolando M. Puno; Stacie L. Grossfeld; Stephen L. Henry; David Seligson; James Harkess; Tsu-Min Tsai

Publisher
John Wiley and Sons
Year
1996
Tongue
English
Weight
597 KB
Volume
17
Category
Article
ISSN
0738-1085

No coin nor oath required. For personal study only.

✦ Synopsis

Numerous reports list predictive criteria to determine whether Gustilio-type tibial III-B and III-C fractures of the tibia are salvageable. What is lacking are long-term reports of comprehensive functional outcome of these severe injuries. We evaluated the functional outcome of patients with our own seven-scale score. Fifty-four patients with 57 types III-B (n = 41) and III-C (n = 16) open tibial fractures sustained between 1980 and 1989 were recalled for evaluation. There were 45 men and 9 women (average age, 28.4 years; range, 4-68 years). Follow-up periods averaged 48.2 months (range, 12-116 months). Salvage rate for the III-B fractures was 75% (n = 31) and for the III-C fractures 37% (n = 6). We conclude that the functional score is a simple and complete method for assessing the functional outcome of patients undergoing limb salvage procedures.

📜 SIMILAR VOLUMES

Fractionated cyclophosphamide and back t
Fractionated cyclophosphamide and back to back high dose methotrexate and cytosine arabinoside improves outcome in patients with stage III high grade small non-cleaved cell lymphomas (Snccl): A randomized trial of the pediatric oncology group
✍ Brecher, Martin L.; Schwenn, Molly R.; Coppes, Max J.; Bowman, W. Paul; Link, Mi 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 279 KB 👁 2 views

## Background: The pediatric oncology group (pog) conducted a two-arm, randomized study for the treatment of children and adolescents with stage iii small, non-cleaved cell lymphoma (snccl). regimen a, based on the group's previous best treatment for this group of patients, included cyclophosphamid

Phase I/II trial of paclitaxel by 1-hour
Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma
✍ John D. Hainsworth; Howard A. Burris III; Joan B. Erland; Lisa H. Morrissey; Ant 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB 👁 3 views

## BACKGROUND. The combination of paclitaxel and carboplatin is widely used in the treatment of patients with advanced nonsmall cell lung carcinoma. In this Phase I/II study the authors evaluated the feasibility, toxicity, and efficacy of adding a third active antineoplastic agent, gemcitabine, to

Précis de pathologie chirurgicale. By Bé
Précis de pathologie chirurgicale. By Bégouin and F. Papin, Henri Bourgeois, Pierre Duval and J. Gatellier, Gosset and D. Petit-Dutaillis, E. Jeanbrau, Lecène, Lenormant, R. Proust and R. Soupault, L. Tixier and M. Patel. Fifth edition. Demy 8vo, in 6 Vols. Pp. 5542, with 1918 illustrations. Vol. I, General Surgical Pathology, Diseases of the Tissues; Vol. II, Head, Spine, Pelvis; Vol. III, Neck, Thorax, Mammary Glands; Vol. IV, Abdomen; Vol. V, Male Genital Organs, Urinary Pathology, Gynæcology Vol. VI, Fractures and Dislocations, Acquired and Congenital Affections of the Limbs. 1928. Paris: Masson et Cie. Each volume, Sewed, Fr. 45; Cloth, Fr. 55. Complete, sewed, Fr. 270; cloth, Fr. 330
📂 Article 📅 1929 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB 👁 1 views
2009 Focused Updates: ACC/AHA Guidelines
2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update) : A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
✍ Frederick G. Kushner; Mary Hand; Sidney C. Smith Jr; Spencer B. King III; Jeffre 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English